TABLE 2.
Demographic Description of Study Subjects in the Validation Cohort
| IBS (n = 14) | UCR + IBS (n = 9) | UCA (n = 15) | |
|---|---|---|---|
| Male/female | 5/9 | 7/2 | 9/6 |
| Age, median (range), y | 28.5 (20–52) | 41 (32–69) | 48 (31–67) |
| Mayo score, low/intermediate/higha | NA | 7/2/0 | 0/6/9 |
| IBS subgroup IBS-D/IBS-C/IBS-Mb | 6/0/8 | 4/0/5 | NA |
| Calprotectin, median (range), μg/g | 18 (<15–120) | *d | 551 (34–3519) |
| Current treatment | |||
| None | 14 | 1 | 5 |
| 5-aminosalicylic acid | 0 | 7 | 10 |
| Thiopurine | 0 | 1 | 0 |
| Anti-TNF | 0 | 0 | 0 |
| Systemic steroids | 0 | 0 | 0 |
| Disease extent | |||
| Proctitis | NA | 1 | 2 |
| Left-sided colitis | NA | 3 | 5 |
| Extensive colitis | NA | 5 | 8 |
| IBS-SSS, moderate/severec | 10/4 | *d | NA |
aMayo score, disease activity index for UC, low ≤2 pts, intermediate 3–5 pts, high ≥6 pts.
bSubclassification of IBS, predominant diarrhea (IBS-D), predominant constipation (IBS-C), predominant mixed symptoms (IBS-M).
cIBS-SSS (IBS–severity score system), moderate >175 pts, severe >300 pts.
dNonavailable patient information.